Jazz Pharmaceuticals (JAZZ) Tops Q1 EPS by 51c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $214.00 -0.3%
EPS Growth %: -22.5%
Financial Fact:
Total operating expenses: 237.93M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -22.5%
Financial Fact:
Total operating expenses: 237.93M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $3.67, $0.51 better than the analyst estimate of $3.16. Revenue for the quarter came in at $508.2 million versus the consensus estimate of $465.95 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2019 EPS of $14.30-$15.00, versus the consensus of $14.60. Jazz Pharmaceuticals sees FY2019 revenue of $2.05-2.13 billion, versus the consensus of $2.07 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Meta's capital-raising plans expose a major weakness in the AI boom
- Jazz Pharmaceuticals (JAZZ) PT Lowered to $314 at Morgan Stanley
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
